 Product Development
Next Generation Antibody Fragments
|
|
Some of the most commercially successful protein drugs are beginning to lose either their original patent protection or their marketing exclusivity. Examples of such proteins are interferon-alfa, erythropoietin (EPO), human growth hormone (HGH) and human insulin.
Assuming market penetration close to that of traditional drugs, the global market for 'biosimilar' protein therapeutics could potentially exceed US$2 billion. PEGylation as a means of adapting and improving existing protein therapeutics is ideally suited to the biosimilars market.
- Extend clinical use without compromising therapeutic equivalence
- Allow a well-defined USP
- Underpin product life cycle management
- Overcome patent expiry
|
Privacy Policy | Terms of Use | Browsing
